Xlife Sciences AG
Develops and commercializes early-stage life sciences research projects.
XLS | SW
Overview
Corporate Details
- ISIN(s):
- CH0461929603 (+1 more)
- LEI:
- 984500AH590BE88BB517
- Country:
- Switzerland
- Address:
- Talacker 35, 8001 Zürich
Description
Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-22 01:00 |
Xlife Sciences AG erreicht bedeutenden Meilenstein in der Entwicklung von Radio…
|
German | HTML • 9.1 KB | ||
| 2023-12-20 07:00 |
Xlife Sciences AG paves the way for the next successful out-licensing and annou…
|
English | HTML • 11.8 KB | ||
| 2023-12-20 01:00 |
Xlife Sciences AG paves the way for the next successful out-licensing and annou…
|
English | HTML • 9.9 KB | ||
| 2023-12-20 01:00 |
Xlife Sciences AG ebnet Weg für nächste erfolgreiche Auslizenzierung und verkün…
|
German | HTML • 11.2 KB | ||
| 2023-12-18 07:00 |
Revolutionary AI Algorithm Prostate.Carcinoma.ai Achieves EU MDR Class IIa Regi…
|
English | HTML • 10.8 KB | ||
| 2023-12-18 01:00 |
Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Re…
|
English | HTML • 10.2 KB | ||
| 2023-12-18 01:00 |
Revolutionärer KI-Algorithmus «Prostate.Carcinoma.ai» erhält EU MDR Klasse IIa …
|
German | HTML • 14.0 KB | ||
| 2023-10-18 07:00 |
Successful exit of portfolio company and major invest in AI and digital health …
|
English | HTML • 15.5 KB | ||
| 2023-10-18 02:00 |
Successful exit of portfolio company and major invest in AI and digital health …
|
English | HTML • 14.7 KB | ||
| 2023-10-18 02:00 |
Erfolgreicher Exit eines Portfolio-Unternehmens und bedeutende Investition in K…
|
German | HTML • 19.7 KB | ||
| 2023-09-29 07:00 |
ESG Report shows status quo and outlines path for future sustainability improve…
|
English | HTML • 13.4 KB | ||
| 2023-09-29 02:00 |
ESG Report shows status quo and outlines path for future sustainability improve…
|
English | HTML • 11.4 KB | ||
| 2023-09-29 02:00 |
ESG-Bericht zeigt Status Quo und skizziert den Weg für zukünftige Nachhaltigkei…
|
German | HTML • 12.6 KB | ||
| 2023-09-21 07:00 |
Xlife Sciences with significant progress in H1 2023
|
English | HTML • 18.5 KB | ||
| 2023-09-21 02:00 |
Xlife Sciences with significant progress in H1 2023
|
English | HTML • 12.4 KB |
Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xlife Sciences AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-15 | N/A | Executive member | Buy | None | 6,000.00 CHF |
| 2022-06-15 | N/A | Executive member | Buy | None | 3,000.00 CHF |
| 2022-06-14 | N/A | Executive member | Buy | None | 15,500.00 CHF |
| 2022-06-10 | N/A | Executive member | Buy | None | 6,728.90 CHF |
| 2022-06-07 | N/A | Executive member | Buy | None | 34,800.00 CHF |
| 2022-06-03 | N/A | Executive member | Buy | None | 3,540.00 CHF |
| 2022-05-24 | N/A | Executive member | Buy | None | 3,400.00 CHF |
| 2022-05-17 | N/A | Executive member | Buy | None | 10,794.20 CHF |
| 2022-05-13 | N/A | Executive member | Buy | None | 3,690.00 CHF |
| 2022-05-10 | N/A | Executive member | Buy | None | 1,935.00 CHF |
Peer Companies
